Apolipoprotein F is reduced in humans with steatosis and controls plasma triglyceride-rich lipoprotein metabolism.
Journal
Hepatology (Baltimore, Md.)
ISSN: 1527-3350
Titre abrégé: Hepatology
Pays: United States
ID NLM: 8302946
Informations de publication
Date de publication:
01 04 2023
01 04 2023
Historique:
received:
02
12
2021
accepted:
07
06
2022
pubmed:
24
6
2022
medline:
22
3
2023
entrez:
23
6
2022
Statut:
ppublish
Résumé
NAFLD affects nearly 25% of the global population. Cardiovascular disease (CVD) is the most common cause of death among patients with NAFLD, in line with highly prevalent dyslipidemia in this population. Increased plasma triglyceride (TG)-rich lipoprotein (TRL) concentrations, an important risk factor for CVD, are closely linked with hepatic TG content. Therefore, it is of great interest to identify regulatory mechanisms of hepatic TRL production and remnant uptake in the setting of hepatic steatosis. To identify liver-regulated pathways linking intrahepatic and plasma TG metabolism, we performed transcriptomic analysis of liver biopsies from two independent cohorts of obese patients. Hepatic encoding apolipoprotein F ( APOF ) expression showed the fourth-strongest negatively correlation with hepatic steatosis and the strongest negative correlation with plasma TG levels. The effects of adenoviral-mediated human ApoF (hApoF) overexpression on plasma and hepatic TG were assessed in C57BL6/J mice. Surprisingly, hApoF overexpression increased both hepatic very low density lipoprotein (VLDL)-TG secretion and hepatic lipoprotein remnant clearance, associated a ~25% reduction in plasma TG levels. Conversely, reducing endogenous ApoF expression reduced VLDL secretion in vivo , and reduced hepatocyte VLDL uptake by ~15% in vitro . Transcriptomic analysis of APOF -overexpressing mouse livers revealed a gene signature related to enhanced ApoB-lipoprotein clearance, including increased expression of Ldlr and Lrp1 , among others. These data reveal a previously undescribed role for ApoF in the control of plasma and hepatic lipoprotein metabolism by favoring VLDL-TG secretion and hepatic lipoprotein remnant particle clearance.
Sections du résumé
BACKGROUND
NAFLD affects nearly 25% of the global population. Cardiovascular disease (CVD) is the most common cause of death among patients with NAFLD, in line with highly prevalent dyslipidemia in this population. Increased plasma triglyceride (TG)-rich lipoprotein (TRL) concentrations, an important risk factor for CVD, are closely linked with hepatic TG content. Therefore, it is of great interest to identify regulatory mechanisms of hepatic TRL production and remnant uptake in the setting of hepatic steatosis.
APPROACH AND RESULTS
To identify liver-regulated pathways linking intrahepatic and plasma TG metabolism, we performed transcriptomic analysis of liver biopsies from two independent cohorts of obese patients. Hepatic encoding apolipoprotein F ( APOF ) expression showed the fourth-strongest negatively correlation with hepatic steatosis and the strongest negative correlation with plasma TG levels. The effects of adenoviral-mediated human ApoF (hApoF) overexpression on plasma and hepatic TG were assessed in C57BL6/J mice. Surprisingly, hApoF overexpression increased both hepatic very low density lipoprotein (VLDL)-TG secretion and hepatic lipoprotein remnant clearance, associated a ~25% reduction in plasma TG levels. Conversely, reducing endogenous ApoF expression reduced VLDL secretion in vivo , and reduced hepatocyte VLDL uptake by ~15% in vitro . Transcriptomic analysis of APOF -overexpressing mouse livers revealed a gene signature related to enhanced ApoB-lipoprotein clearance, including increased expression of Ldlr and Lrp1 , among others.
CONCLUSION
These data reveal a previously undescribed role for ApoF in the control of plasma and hepatic lipoprotein metabolism by favoring VLDL-TG secretion and hepatic lipoprotein remnant particle clearance.
Identifiants
pubmed: 35735979
pii: 01515467-202304000-00024
doi: 10.1002/hep.32631
pmc: PMC10026963
doi:
Substances chimiques
apolipoprotein F
0
Lipoproteins
0
Apolipoproteins
0
Triglycerides
0
Lipoproteins, VLDL
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1287-1302Informations de copyright
Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc.
Références
Nat Commun. 2015 Mar 10;6:6356
pubmed: 25754609
Biochim Biophys Acta. 2014 Jul;1841(7):919-33
pubmed: 24721265
J Lipid Res. 2008 Jan;49(1):127-35
pubmed: 17901467
Atherosclerosis. 2014 Mar;233(1):234-41
pubmed: 24529150
J Biol Chem. 2019 Aug 2;294(31):11805-11816
pubmed: 31197036
J Clin Invest. 1998 Jul 1;102(1):130-5
pubmed: 9649566
J Clin Invest. 2020 Mar 2;130(3):1453-1460
pubmed: 31805015
Arterioscler Thromb Vasc Biol. 2005 Aug;25(8):1697-703
pubmed: 15947244
J Lipid Res. 2019 Nov;60(11):1868-1879
pubmed: 31511396
Arterioscler Thromb Vasc Biol. 2008 Jul;28(7):1225-36
pubmed: 18565848
Front Physiol. 2015 Nov 20;6:342
pubmed: 26635628
JCI Insight. 2017 Jul 6;2(13):
pubmed: 28679947
Genes Dev. 2013 Mar 1;27(5):459-84
pubmed: 23475957
Nat Rev Gastroenterol Hepatol. 2020 Mar;17(3):169-183
pubmed: 32015520
PLoS One. 2012;7(2):e31616
pubmed: 22363685
J Am Coll Cardiol. 2009 Dec 29;55(1):42-4
pubmed: 20117362
Nat Metab. 2021 Nov;3(11):1476-1483
pubmed: 34750571
Clin Chim Acta. 2020 Jan;500:81-86
pubmed: 31770510
Arterioscler Thromb Vasc Biol. 2013 Nov;33(11):2481-90
pubmed: 23990208
Eur Heart J. 2021 Dec 14;42(47):4791-4806
pubmed: 34472586
BMC Med Genomics. 2019 Jun 3;12(1):80
pubmed: 31159817
Am J Pathol. 1985 Nov;121(2):200-11
pubmed: 3840653
Gastroenterology. 2008 Feb;134(2):424-31
pubmed: 18242210
J Lipid Res. 1994 May;35(5):836-47
pubmed: 8071606
Biochemistry. 1978 Mar 21;17(6):1032-6
pubmed: 204339
Arterioscler Thromb Vasc Biol. 2009 Jan;29(1):40-6
pubmed: 19008531
Arterioscler Thromb Vasc Biol. 2011 Sep;31(9):2144-50
pubmed: 21778423
Eur Heart J. 2013 Jun;34(24):1826-33
pubmed: 23248205
J Hepatol. 2014 Mar;60(3):633-42
pubmed: 24269473
J Lipid Res. 1999 Jan;40(1):1-16
pubmed: 9869645
Circ Res. 2013 May 24;112(11):1479-90
pubmed: 23542898
Nat Metab. 2019 Jun;1(6):604-614
pubmed: 31701087
Gastroenterology. 2014 Mar;146(3):726-35
pubmed: 24316260
Nat Genet. 2014 Apr;46(4):352-6
pubmed: 24531328
J Clin Endocrinol Metab. 2016 Nov;101(11):4151-4160
pubmed: 27588438
PLoS One. 2013 Nov 20;8(11):e79473
pubmed: 24278138
Arterioscler Thromb Vasc Biol. 2013 Sep;33(9):2065-74
pubmed: 23846497
Proc Natl Acad Sci U S A. 2002 Oct 1;99(20):12753-8
pubmed: 12242332
Nat Genet. 2008 Dec;40(12):1461-5
pubmed: 18820647
J Atheroscler Thromb. 2013;20(4):380-90
pubmed: 23370704
Sci Rep. 2019 Dec 24;9(1):19785
pubmed: 31874999
J Biol Chem. 2007 Jun 22;282(25):18602-18612
pubmed: 17452316
J Lipid Res. 2013 May;54(5):1466-76
pubmed: 23417739
J Clin Invest. 2005 May;115(5):1343-51
pubmed: 15864352
Hepatology. 2020 Nov;72(5):1605-1616
pubmed: 32043613
Mol Metab. 2020 Dec;42:101092
pubmed: 33010471